.png)
.png)
President & Chief Operating Officer
OptiNose Inc.
Yardley, PA, United States
Dr. Mahmoud is currently President of Optinose, Inc., which he co-founded in 2010. Prior to Optinose, Dr. Mahmoud spent 14 years at Johnson & Johnson where he was Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. At J&J he also held senior roles in the Pharmaceutical sector and, in addition to management board responsibilities at several operating companies, led a range of functions in both R&D and commercial organizations. Dr. Mahmoud participated in the development, launch and/or commercialization of dozens of pharmaceutical and medical device products spanning multiple therapeutic categories.
Previously, Dr. Mahmoud served 10 years on active duty and an additional 10 reserve years in the United States Army, earning the rank of Lieutenant Colonel and serving as a battalion surgeon and flight surgeon. He received numerous commendations and decorations for his service in various patient care, research and academic positions, including Asst Professor of Medicine at USUHS, culminating in his final role as head of the Department of Epidemiology at the Walter Reed Army Institute of Research and inaugural leader of a policy research and analysis activity in support of the Assistant Secretary of Defense (Health Affairs).
Dr. Mahmoud is an accomplished international scientist, has made hundreds of scientific presentations, published many peer-reviewed papers and textbook chapters, and served as a scientific reviewer for a number of journals and textbooks.
Dr. Mahmoud earned a Master’s degree with a focus in healthcare management and policy from Harvard, an MD from the first Honors Program in Medical Education at the University of Miami and board certifications in both Public Health/Preventive Medicine and in Internal Medicine. He holds certificates from the Program in Clinical Effectiveness (Harvard Medical School) and in Advanced Tropical Medicine (Walter Reed).
I do not have any relevant financial / non-financial relationships with any proprietary interests.
Friday, October 21, 2022
4:15 PM – 4:27 PM US ET